Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals

Rilpivirine (RPV), the latest nonnucleoside reverse transcriptase inhibitor active against HIV-1, is prescribed in a standard dosage of 25 mg once a day in combination with emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF). The aim of this observational study was to characterize the RPV ph...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Antimicrob Agents Chemother
Hlavní autoři: Aouri, Manel, Barcelo, Catalina, Guidi, Monia, Rotger, Margalida, Cavassini, Matthias, Hizrel, Cédric, Buclin, Thierry, Decosterd, Laurent A., Csajka, Chantal
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2016
Témata:
Antiviral Agents
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5192124/
https://ncbi.nlm.nih.gov/pubmed/27799217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00899-16
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky